Severe acute respiratory syndrome coronavirus

Preliminary results suggest nearly 6% of Montreal children tested from October to April had antibodies to SARS-CoV-2

Retrieved on: 
Tuesday, May 18, 2021

As an overall average, 5.8% of participating children were found to have antibodies to SARS-CoV-2, the virus that causes COVID-19.

Key Points: 
  • As an overall average, 5.8% of participating children were found to have antibodies to SARS-CoV-2, the virus that causes COVID-19.
  • By April 2021, in the third wave, 8.9% of the students tested had antibodies.
  • \xe2\x80\x9cThe results also suggest that seroprevalence is higher in neighbourhoods with lower socio-economic indexes and at a greater percentage for racialized residents.
  • The blood samples were taken from 354 children in daycare, 725 children in elementary schools, and 553 students in high schools.

Celltrion Confirms Neutralising Potency Against Emerging SARS-CoV-2 Variants With Anti-COVID-19 Monoclonal Antibody Treatment regdanvimab (CT-P59)

Retrieved on: 
Tuesday, May 18, 2021

CT-P59 is known to successfully neutralise the SARS-CoV-2 variants first identified in the UK (B.1.1.7), California (B.1.427/B.1.429), Brazil (P.2), in addition to the previously identified six variant genome mutations of SARS-CoV-2 (variants S\xc2\xb7L\xc2\xb7V\xc2\xb7G\xc2\xb7GH\xc2\xb7GR).\n\xe2\x80\x9cThe emergence of SARS-CoV-2 variants has created great concern across the globe.

Key Points: 
  • CT-P59 is known to successfully neutralise the SARS-CoV-2 variants first identified in the UK (B.1.1.7), California (B.1.427/B.1.429), Brazil (P.2), in addition to the previously identified six variant genome mutations of SARS-CoV-2 (variants S\xc2\xb7L\xc2\xb7V\xc2\xb7G\xc2\xb7GH\xc2\xb7GR).\n\xe2\x80\x9cThe emergence of SARS-CoV-2 variants has created great concern across the globe.
  • \xe2\x80\x9cMonoclonal antibodies have the potential to alleviate symptoms and prevent progression to severe disease in patients with mild to moderate COVID-19.
  • Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries.
  • For more information please visit: https://www.celltrionhealthcare.com/en-us .\nCT-P59 was identified as a potential treatment for COVID-19 through screening of antibody candidates and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus.

Roche receives FDA authorisation for testing of asymptomatic people with the cobas SARS-CoV-2 Test to help control the spread of COVID-19

Retrieved on: 
Tuesday, May 18, 2021

"\nAsymptomatic testing with the cobas SARS-CoV-2 Test is also available in countries accepting the CE mark.

Key Points: 
  • "\nAsymptomatic testing with the cobas SARS-CoV-2 Test is also available in countries accepting the CE mark.
  • It has been authorised by the FDA under an EUA for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C.
  • The test has been authorised only for the detection of RNA from SARS-CoV-2 virus and diagnosis of SARS-CoV-2 virus infection, not for any other viruses or pathogens.
  • Specimens with low SARS-CoV-2 RNA concentrations may not be detected in sample pools due to the decreased sensitivity of pooled testing.

Roche receives FDA authorisation for testing of asymptomatic people with the cobas SARS-CoV-2 Test to help control the spread of COVID-19

Retrieved on: 
Tuesday, May 18, 2021

"\nAsymptomatic testing with the cobas SARS-CoV-2 Test is also available in countries accepting the CE mark.

Key Points: 
  • "\nAsymptomatic testing with the cobas SARS-CoV-2 Test is also available in countries accepting the CE mark.
  • It has been authorised by the FDA under an EUA for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C.
  • The test has been authorised only for the detection of RNA from SARS-CoV-2 virus and diagnosis of SARS-CoV-2 virus infection, not for any other viruses or pathogens.
  • Specimens with low SARS-CoV-2 RNA concentrations may not be detected in sample pools due to the decreased sensitivity of pooled testing.

Cocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, May 17, 2021

\xe2\x80\x9cAs discussed in our coronavirus update release earlier this month, we continue developing novel SARS-CoV-2 oral protease inhibitors and are rapidly advancing lead compounds.

Key Points: 
  • \xe2\x80\x9cAs discussed in our coronavirus update release earlier this month, we continue developing novel SARS-CoV-2 oral protease inhibitors and are rapidly advancing lead compounds.
  • That agreement provides Cocrystal with an exclusive, royalty-bearing license to develop and commercialize therapeutic, diagnostic and prophylactic products against coronaviruses, caliciviruses and picornaviruses based on antivirals discovered by KSURF.
  • The Company believes the 3CL protease has the ability to convert the inactive SARS-CoV-2 replication enzymes into the active form.
  • As anticipated, Cocrystal reported no revenues for the first quarter of 2021 compared with $461,000 in revenues for the first quarter of 2020.

Eurofins at the Forefront of Innovation with New Developments for Detection and Identification of Emerging COVID-19 Variants of Concern

Retrieved on: 
Monday, May 17, 2021

b'Eurofins Technologies continues to develop a range of diagnostic solutions for COVID-19, particularly in response to the threat of emerging mutations.

Key Points: 
  • b'Eurofins Technologies continues to develop a range of diagnostic solutions for COVID-19, particularly in response to the threat of emerging mutations.
  • Eurofins Technologies will continue to invest in R&D to develop further reliable, high-quality testing solutions for the SARS-CoV-2 virus and its variants.\nGSD NovaPrime\xc2\xae Plus SARS-CoV-2 kit is a multiplex RT-PCR that can detect a SARS-CoV-2 infection and identify mutations of concern in one reaction.
  • It is of relevance to the global pandemic situation as this mutation is related to both an increase in infectivity and reduction of immune response in vaccinated subjects.
  • With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins\xe2\x80\x99 companies offer a portfolio of over 200,000 analytical methods.\nEurofins Shares are listed on Euronext Paris Stock Exchange.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210516005032/en/\n'

Quidel’s QuickVue® At-Home OTC COVID-19 Test Now Available for Sale Through Amazon

Retrieved on: 
Friday, May 14, 2021

The QuickVue\xc2\xae At-Home OTC COVID-19 Test has not been FDA cleared or approved.

Key Points: 
  • The QuickVue\xc2\xae At-Home OTC COVID-19 Test has not been FDA cleared or approved.
  • An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S.
  • For more information about Quidel, visit quidel.com .\nThis press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties.
  • You are cautioned not to place undue reliance on these forward-looking statements, which reflect management\xe2\x80\x99s analysis only as of the date of this press release.

QIAGEN Receives U.S. FDA Emergency Use Authorization for Fast and Easy-to-Use Digital Test to Detect SARS-CoV-2 Coronavirus Antibodies

Retrieved on: 
Wednesday, May 12, 2021

QIAGEN\xe2\x80\x99s technology detects total antibodies (Total immunoglobulin) specific to SARS-CoV-2 immune response \xe2\x80\x93 while most other tests currently identify only selected antibodies.\nThe QIAreach Anti-SARS-CoV-2 Total Test was developed in partnership with Ellume, an Australian digital diagnostics company.

Key Points: 
  • QIAGEN\xe2\x80\x99s technology detects total antibodies (Total immunoglobulin) specific to SARS-CoV-2 immune response \xe2\x80\x93 while most other tests currently identify only selected antibodies.\nThe QIAreach Anti-SARS-CoV-2 Total Test was developed in partnership with Ellume, an Australian digital diagnostics company.
  • QIAGEN is the only company that has developed both an antibody and a T-cell test to track immune responses.
  • The QIAreach Anti-SARS-CoV-2 Total Test generates easy-to-read results on the digital eHub platform.
  • Each QIAreach eHub can handle up to eight samples on eight eSticks simultaneously, with each eStick test running independently.

Tevogen Bio’s TVGN-489, an Allogeneic SARS-CoV-2 Specific Cytotoxic T Cell Therapy, Demonstrates Strong Anti-Viral Activity in Preclinical Study, as Presented by Professor Neal Flomenberg of Thomas Jefferson University

Retrieved on: 
Tuesday, May 11, 2021

b'Tevogen Bio, a clinical stage biotechnology company, announced that its investigational COVID-19 therapy, TVGN-489, demonstrated strong antiviral activity against SARS-CoV-2 in the preclinical study.

Key Points: 
  • b'Tevogen Bio, a clinical stage biotechnology company, announced that its investigational COVID-19 therapy, TVGN-489, demonstrated strong antiviral activity against SARS-CoV-2 in the preclinical study.
  • COVID-19 reactive cells comprised 70% or more of the cells in initial batches of this product.
  • These data suggest the viability of TVGN-489 as a potentially curative treatment for COVID-19.
  • Neal Flomenberg is the Chairman of the Department of Medical Oncology and Deputy Director of the Sidney Kimmel Cancer Center at Jefferson University in Philadelphia.

Oxford Immunotec’s T-SPOT.COVID Test is Used in the COV-AD Clinical Study to Investigate the Immunological Response to SARS-CoV-2 Infection in Patients with Primary and Secondary Antibody Deficiency

Retrieved on: 
Tuesday, May 11, 2021

The study will monitor the clinical course of SARS-CoV-2 infection and the immunological response of patients to vaccination.

Key Points: 
  • The study will monitor the clinical course of SARS-CoV-2 infection and the immunological response of patients to vaccination.
  • The study will collect samples from 13 sites around the UK.\nThe COV-AD study aims to build on the UK Primary Immunodeficiency Network (UKPIN) data by determining the prevalence, course and outcomes of SARS-CoV-2 infection in patients with Primary Antibody Deficiency (PAD)/Secondary Antibody Deficiency (SAD).
  • Development of anti-SARS-CoV-2 immunity to COVID infection or vaccination will be tested by blood sampling to measure specific antibody titre and for the presence of anti-SARS-CoV-2 T cells.
  • Our leading product, the T-SPOT.TB test, is used for diagnosing infection with Tuberculosis, the world\xe2\x80\x99s largest cause of death from infectious disease.